Shr-7590

Phase 1

Guangdong Hengrui Pharmaceutical Co., Ltd

Shr-7590 is one of 2 therapeutic programs targeting Moderate to Severe Ulcerative Colitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Moderate to Severe Ulcerative ColitisNot yet recruiting

Moderate to Severe Ulcerative ColitisPhase 1

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Moderate to Severe Ulcerative Colitis

#DrugCompanyPhaseTrials

Shr-7590

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 1

1 2

Vixarelimab

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Moderate to Severe Ulcerative Colitis

NCT07758101

Clinical

Trials by Indication[1]

Moderate to Severe Ulcerative Colitis1 trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-7590 Via Subcutaneous or Intravenous Administration in Chinese Healthy Participants and Patients With Moderate-to-Severe Ulcerative Colitis

Not yet recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT07758101·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Shr-7590. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Shr-7590. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Guangdong Hengrui Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Guangdong Hengrui Pharmaceutical Co., Ltd

Shr-7590

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Moderate to Severe Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News